The Oncology Institute, Inc. (NASDAQ:TOI) Sees Large Growth in Short Interest

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 324,100 shares, a growth of 86.8% from the December 31st total of 173,500 shares. Based on an average daily trading volume, of 1,740,000 shares, the short-interest ratio is currently 0.2 days. Currently, 0.9% of the company's stock are short sold.

Insider Activity at Oncology Institute

In other Oncology Institute news, Director Brad Hively bought 250,000 shares of Oncology Institute stock in a transaction dated Tuesday, November 26th. The stock was acquired at an average cost of $0.17 per share, with a total value of $42,500.00. Following the completion of the acquisition, the director now owns 616,753 shares of the company's stock, valued at approximately $104,848.01. This represents a 68.17 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.50% of the company's stock.

Institutional Investors Weigh In On Oncology Institute

A hedge fund recently raised its stake in Oncology Institute stock. HighTower Advisors LLC grew its holdings in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 190.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,362 shares of the company's stock after purchasing an additional 53,382 shares during the period. HighTower Advisors LLC owned approximately 0.11% of Oncology Institute worth $27,000 at the end of the most recent reporting period. Institutional investors own 36.86% of the company's stock.

Oncology Institute Stock Performance

TOI traded down $0.01 on Friday, hitting $1.00. 1,568,685 shares of the company traded hands, compared to its average volume of 839,682. Oncology Institute has a 12-month low of $0.13 and a 12-month high of $2.20. The company has a 50 day moving average of $0.36 and a 200-day moving average of $0.35. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91. The stock has a market capitalization of $75.56 million, a PE ratio of -1.28 and a beta of 0.13.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.